# Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign

Source: https://onco.cc/trials/nct03932331/  
OnCo record `nct03932331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Acalabrutinib in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies is a phase 1/2 interventional study registered as NCT03932331 by AstraZeneca, with 105 participants enrolled, started 2020-04-29 and due to reach its primary completion in 2022-12-22. Interventions recorded: Acalabrutinib. Conditions listed: Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT03932331
- Phase: 1/2
- Setting: A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
- Sponsor: AstraZeneca
- Enrolled: 105
- Outcomes: Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR): Phase II MCL 82.4% vs Phase II CLL 86.7%; Phase II: Percentage of Participants With Overall Survival (OS) at Month 6: Phase II MCL vs Phase II CLL 96.7%

## Sources

- ClinicalTrials.gov NCT03932331: https://clinicaltrials.gov/study/NCT03932331

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03932331.json